Oligonucleotide Synthesis Market Size 2026-2030
The oligonucleotide synthesis market size is valued to increase by USD 5.59 billion, at a CAGR of 17.8% from 2025 to 2030. Technological advancements in oligonucleotide synthesis methods will drive the oligonucleotide synthesis market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 46.1% growth during the forecast period.
- By Application - PCR primers segment was valued at USD 1.01 billion in 2024
- By End-user - Pharmaceutical and biotechnology companies segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 7.01 billion
- Market Future Opportunities: USD 5.59 billion
- CAGR from 2025 to 2030 : 17.8%
Market Summary
- The oligonucleotide synthesis market is defined by its critical role in advancing life sciences, from fundamental research to clinical applications. Growth is propelled by escalating demand for nucleic acid-based therapies and precision diagnostics, where custom-synthesized DNA and RNA sequences are indispensable.
- Key trends include the industry's pivot towards more sustainable and efficient production methods, such as enzymatic synthesis, which offer higher fidelity and a reduced environmental footprint compared to traditional chemical processes. Concurrently, the increasing adoption of automated, high-throughput platforms is enabling the rapid production of complex sequences necessary for drug discovery and synthetic biology.
- However, the market grapples with significant challenges, including the high cost of manufacturing therapeutic-grade oligonucleotides and navigating stringent, often disparate, international regulatory frameworks. For instance, a contract development and manufacturing organization (CDMO) scaling up production for a novel gene therapy must balance GMP compliance and rigorous quality control with cost-containment strategies to ensure commercial viability.
- This involves optimizing every step, from raw material sourcing and synthesis to downstream purification and final formulation, to meet strict purity specifications without rendering the final product cost-prohibitive for healthcare systems.
What will be the Size of the Oligonucleotide Synthesis Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Oligonucleotide Synthesis Market Segmented?
The oligonucleotide synthesis industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Application
- PCR primers
- PCR assays and panels
- DNA microarrays
- Fluorescence in situ hybridization
- Others
- End-user
- Pharmaceutical and biotechnology companies
- Research and academic institutes
- Diagnostic laboratories
- Hospitals
- Product
- Oligonucleotide products
- Reagents and consumables
- Synthesis equipment
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Asia
- Rest of World (ROW)
- North America
By Application Insights
The pcr primers segment is estimated to witness significant growth during the forecast period.
The market is segmented by application, end-user, product, and geography. The PCR primers segment is foundational, providing essential research tools for genetic amplification. Demand is driven by expanding genomic research and the increasing prevalence of molecular diagnostics.
These applications necessitate high-quality sequences for targeting genetic markers in infectious and hereditary diseases. Manufacturing relies on sophisticated methods like phosphoramidite chemistry and emerging enzymatic synthesis to ensure high purity for diagnostic assays.
As high-throughput synthesis supports large-scale projects, innovations in oligo analysis and oligonucleotide purification have improved primer performance, reducing non-specific binding by over 15%.
This advancement is critical for the development of therapeutic applications, including antisense oligonucleotides and small interfering RNAs, which require flawless gmp-compliant synthesis for large-scale synthesis.
The PCR primers segment was valued at USD 1.01 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 46.1% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Oligonucleotide Synthesis Market Demand is Rising in North America Request Free Sample
The geographic landscape of the oligonucleotide synthesis market is characterized by regional specialization and evolving growth dynamics.
North America continues to dominate, accounting for over 46% of the market's incremental growth, driven by its dense ecosystem of biotechnology firms and substantial R&D funding for nucleic acid-based therapies.
Europe focuses on high-quality, sustainable gmp production, with stringent regulations fostering innovation in green chemistry and advanced therapeutic oligo manufacturing.
Meanwhile, Asia is rapidly emerging as a key manufacturing hub, with investments in local gmp facilities leading to a 15% increase in regional capacity for custom dna/rna oligos.
This expansion supports both regional demand for oligo-based diagnostics and global supply chains. Key activities include chemical modification for enhanced oligonucleotide stability, gene silencing research, and the production of high-purity oligonucleotides for bioconjugation techniques.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The global oligonucleotide synthesis market 2026-2030 is increasingly shaped by the sophisticated demands of therapeutic applications, pushing innovation beyond basic synthesis. A central theme is the gmp manufacturing of therapeutic oligonucleotides, where the debate between enzymatic versus chemical oligonucleotide synthesis informs investment in scalable production platforms.
- As companies advance novel candidates, developing robust cmc strategies for oligo drugs becomes paramount for navigating complex regulatory pathways for nucleic acid drugs. This includes rigorous analytical methods for oligo impurity profiling and thorough oligonucleotide stability and degradation studies to ensure product safety and efficacy.
- Concurrently, advances in oligonucleotide purification technology are critical for achieving the high purity required for clinical use. The adoption of continuous purification processes has improved yields for complex modified oligos by more than 25% over traditional batch methods, a crucial factor for supply chain efficiency.
- Furthermore, the development of effective oligonucleotide delivery systems and formulations remains a key challenge, influencing both bioavailability and therapeutic outcomes. Automation in oligonucleotide synthesis workflows and strategic process optimization for oligo manufacturing are addressing challenges in long oligonucleotide synthesis and helping to manage the cost analysis of large scale oligo synthesis.
- This integration is vital for everything from high-throughput screening with custom oligos to oligonucleotide-based companion diagnostics development, solid-phase vs liquid-phase oligo synthesis considerations, and building resilient supply chain strategies for oligo raw materials.
What are the key market drivers leading to the rise in the adoption of Oligonucleotide Synthesis Industry?
- Technological advancements in oligonucleotide synthesis methods are a key driver of market growth, improving efficiency, scalability, and production sustainability.
- Market growth is fundamentally driven by the expanding pipeline of nucleic acid therapeutics and significant investment in production infrastructure. The escalating demand for oligonucleotides in drug discovery and target validation is compelling firms to enhance scalable oligonucleotide production capabilities.
- Strategic collaborations are shortening development timelines for novel rna therapeutics by an average of six months, accelerating progress in gene modulation.
- Investment in automated synthesis platforms and advanced bioprocessing is leading to the construction of new facilities dedicated to clinical oligo synthesis.
- These expansions are increasing global GMP-compliant capacity by an estimated 25%, crucial for meeting the demands of both solid-phase synthesis and emerging sustainable synthesis methods.
- Innovations in oligo delivery and cmc development are further broadening the therapeutic potential of these molecules.
What are the market trends shaping the Oligonucleotide Synthesis Industry?
- A significant market trend is the shift toward enzymatic and sustainable synthesis methods. This move addresses environmental concerns and scalability challenges associated with traditional chemical approaches.
- Key trends are reshaping the production landscape, driven by a definitive move toward advanced and sustainable technologies. The adoption of enzymatic synthesis and other green oligonucleotide chemistry methods is accelerating, reducing hazardous solvent use by up to 85% compared to traditional approaches. This shift is critical for companies targeting therapeutic grade oligonucleotides for gene therapy and personalized medicine.
- Concurrently, the market is expanding its use of sophisticated research tools like dna microarrays and fluorescence in situ hybridization for molecular diagnostics. Demand for custom oligo services is surging, supported by innovations in dna/rna synthesis that enable complex modified oligonucleotides for applications such as crispr gene editing and synthetic biology.
- The use of advanced synthesis reagents has improved process consistency, with batch-to-batch variability dropping by over 40%.
What challenges does the Oligonucleotide Synthesis Industry face during its growth?
- High manufacturing costs and scalability limitations present a key challenge affecting industry growth, particularly for therapeutic-grade and large-scale production.
- Significant challenges persist around manufacturing costs and regulatory complexities, constraining market expansion. The high cost of goods for therapeutic-grade material, which can account for up to 60% of total manufacturing expense, remains a primary hurdle, particularly for novel liquid-phase synthesis and complex downstream processing techniques. Yield optimization and efficient purification methods are critical but require substantial investment.
- Furthermore, navigating stringent regulatory compliance and maintaining quality assurance across the supply chain presents a major operational challenge. Disparate international standards can extend approval timelines by an additional 12 months, complicating synthesis scale-up. Effective management of raw material sourcing and robust quality control metrics are essential for ensuring sequence fidelity and mitigating risks associated with process analytical technology implementation.
Exclusive Technavio Analysis on Customer Landscape
The oligonucleotide synthesis market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the oligonucleotide synthesis market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Oligonucleotide Synthesis Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, oligonucleotide synthesis market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Agilent Technologies Inc. - Delivering high-quality custom DNA and RNA oligos for research, diagnostics, and therapeutic workflows, ensuring precision for advanced life science applications.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Agilent Technologies Inc.
- Ajinomoto Bio Pharma Services
- Ansa Biotechnologies
- Azenta Inc.
- Bio Synthesis Inc
- Biogen Inc.
- Biotage AB
- Danaher Corp.
- GenScript Biotech Corp.
- Kaneka Corp.
- LGC Ltd.
- Merck KGaA
- Nitto Denko Corp.
- QIAGEN N.V.
- Synbio Technologies LLC
- Syngene International Ltd.
- Thermo Fisher Scientific Inc.
- Twist Bioscience Corp.
- WuXi AppTec Co. Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Oligonucleotide synthesis market
- In November, 2024, Thermo Fisher Scientific entered a strategic collaboration with Twist Bioscience to expand its synthetic biology offerings, including the production of complex oligonucleotides for therapeutic and research applications.
- In January, 2025, Maravai LifeSciences acquired assets and intellectual property from Molecular Assemblies, integrating Fully Enzymatic Synthesis technology to enhance its scalable oligonucleotide and mRNA production capabilities.
- In February, 2025, Agilent Technologies acquired a startup specializing in high-throughput purification technologies for therapeutic oligonucleotides, aiming to improve purity and efficiency in large-scale clinical manufacturing.
- In March, 2025, Dharmacon secured a significant investment to expand its custom oligonucleotide production capacity, with a focus on strengthening automated workflows to meet rising demand from genomics and drug discovery programs.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Oligonucleotide Synthesis Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 309 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 17.8% |
| Market growth 2026-2030 | USD 5593.6 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 15.3% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, China, India, Japan, South Korea, Thailand, Indonesia, Brazil, UAE, Saudi Arabia, Israel, South Africa, Turkey, Argentina and Colombia |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The oligonucleotide synthesis market is sustained by relentless innovation in both chemistry and automation, directly supporting breakthroughs in medicine and life sciences. The expanding applications for antisense oligonucleotides, small interfering rnas, and crispr gene editing components in therapeutic development are fueling demand for gmp-compliant synthesis at an industrial scale.
- This requires a sophisticated approach to therapeutic oligo manufacturing, emphasizing high-purity custom dna/rna oligos and nucleic acid-based therapies. A pivotal boardroom-level decision involves balancing investment in traditional phosphoramidite chemistry platforms against the transition to enzymatic synthesis, a move that impacts long-term operational costs and sustainability targets.
- Firms adopting high-throughput synthesis platforms report a 30% reduction in turnaround times for custom sequence orders, a critical metric for accelerating research and development cycles. Success hinges on mastering complex processes, from gene silencing experiments and oligo-based diagnostics to ensuring robust quality in gmp production, thereby enabling the next generation of precision treatments.
What are the Key Data Covered in this Oligonucleotide Synthesis Market Research and Growth Report?
-
What is the expected growth of the Oligonucleotide Synthesis Market between 2026 and 2030?
-
USD 5.59 billion, at a CAGR of 17.8%
-
-
What segmentation does the market report cover?
-
The report is segmented by Application (PCR primers, PCR assays and panels, DNA microarrays, Fluorescence in situ hybridization, and Others), End-user (Pharmaceutical and biotechnology companies, Research and academic institutes, Diagnostic laboratories, and Hospitals), Product (Oligonucleotide products, Reagents and consumables, and Synthesis equipment) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Technological advancements in oligonucleotide synthesis methods, High manufacturing costs and scalability limitations
-
-
Who are the major players in the Oligonucleotide Synthesis Market?
-
Agilent Technologies Inc., Ajinomoto Bio Pharma Services, Ansa Biotechnologies, Azenta Inc., Bio Synthesis Inc, Biogen Inc., Biotage AB, Danaher Corp., GenScript Biotech Corp., Kaneka Corp., LGC Ltd., Merck KGaA, Nitto Denko Corp., QIAGEN N.V., Synbio Technologies LLC, Syngene International Ltd., Thermo Fisher Scientific Inc., Twist Bioscience Corp. and WuXi AppTec Co. Ltd.
-
Market Research Insights
- Market dynamics are shaped by a strategic push toward advanced therapeutic modalities and enhanced diagnostic precision. The demand for high-purity oligonucleotides for applications in personalized medicine and gene therapy is driving innovation in synthesis and purification technologies. Automated synthesis platforms have become integral, reducing turnaround times for custom sequence design by over 30% and improving batch-to-batch consistency.
- The development of novel oligo delivery mechanisms is expanding the therapeutic window, while robust cmc development strategies ensure a clear path from drug discovery to market. As companies scale up, bioprocessing and analytical characterization techniques are evolving to handle more complex molecules.
- This focus on efficiency and quality is critical, with advanced purification methods increasing final product yields by up to 25%, directly impacting the cost of goods for rna therapeutics and other advanced treatments.
We can help! Our analysts can customize this oligonucleotide synthesis market research report to meet your requirements.